MSH|^~\&||||999997|201012030810||ORU^R01|002056206358214622|P|2.3
PID||PF111|||TEST^PATIENTBILL||19870419|M|||20 MAIN ST^^NEW YORK^NY^10021^||(212)555-1212|||||||
PV1|1||||||^^^^^^^PHYID||||||||U||||||||||||||||||||||||
ORC|RE||||F
OBR|1|LE09999970000099||90204^Protime with Inr|||201010300934|||||||201011091859||^Account^Test^||||||201011091905|||F
OBX|1||2102^INR||0.90|Ratio|2.0 - 3.0|L|||F||||
NTE|1||Recommended therapeutic range: 2.0 - 3.0 Acute M.I., prophylaxis and treatment of venous thrombosis, pulmonary embolism, tissue heart valve, atrial fibrillation, valvular heart disease, prevention of systemic embolism. 2.5 - 3.5 Mechanical Heart Valve.
NTE|2||An INR reference interval of 0.8-1.3 is applicabVH to patients not receiving anti-coagulant medication.
FTS|1|End Of File
